Actinium Pharmaceuticals Publishes Presentation on ATNM-400 Antitumor Activity in Ovarian Cancer Models

Actinium Pharmaceuticals published a medical research presentation on ATNM-400 in preclinical ovarian cancer models. * ATNM-400 monotherapy achieved 93% tumor growth inhibition versus 54% for bevacizumab in the OVCAR-5 mouse model. * Combining ATNM-400 with bevacizumab yielded 85% tumor growth inhibition, providing no additional benefit over ATNM-400 alone. * Following bevacizumab failure, ATNM-400 retained activity with 50% tumor growth inhibition and prolonged survival. * Safety testing showed minimal blood, liver and kidney toxicity in mice; ATNM-400-containing regimens also prolonged survival in an immunocompetent ovarian cancer model. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here